Survival of biological therapeutics in psoriasis: Retrospective analysis of 3-years data in a Turkish Registry, PSORTAKSIS.

Creative Commons License

Özyurt K., Zararsiz G., Ertaş R., Cephe A., Kutlu Ö., Elmas Ö. F., ...Daha Fazla

Turkish journal of medical sciences, cilt.52, ss.58-66, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 52
  • Basım Tarihi: 2022
  • Doi Numarası: 10.3906/sag-2104-339
  • Dergi Adı: Turkish journal of medical sciences
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.58-66
  • Anahtar Kelimeler: Psoriasis, drug survival, anti-TNF, ustekinumab, secukinumab, psoriasis registry, DIFFERENTIAL DRUG SURVIVAL, OBSERVATIONAL COHORT, BRITISH ASSOCIATION, USTEKINUMAB, ADALIMUMAB, THERAPIES, SAFETY
  • Erciyes Üniversitesi Adresli: Evet

Özet

Background/aim: PSORTAKSIS is a psoriasis registry, which is used for follow-up of patients in Kayseri City Education and Research Hospital, Dermatology Clinic since 2016 in Turkey. PSORTAKSIS includes demographic data, follow-up clinical findings, laboratory output, and treatment information of patients. Here, drug survivals of biologic therapeutics (BT) according to three-year data of PSORTAKSIS will be presented.